| Bioactivity | Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165)[1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research[1]. |
| Invitro | Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317)[2]. Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures[3]. |
| In Vivo | Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24 h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1 h after intravitreal administration in rabbits[1].In a study comparing the pharmacokinetics of 0.5 mg of intravitreal Ranibizumab with 1.25 mg of intravitreal Bevacizumab in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7 μg/ml for Bevacizumab and 17.9 μg/ml for Ranibizumab, respectively[1]. |
| Name | Ranibizumab (anti-VEGF) |
| CAS | 347396-82-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mustafa Şahiner, et al. The Effects of Anti-Vascular Endothelial Growth Factor Drugs on Retinal Pigment Epithelial Cell Culture. Turk J Ophthalmol. 2018 Aug;48(4):190-195. [2]. K J Kim, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7(1):53-64. [3]. Richard Filek, et al. Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture. Clin Ophthalmol. 2019 Jul 1;13:1097-1114. |